Multiplex genetic testing in BRCA1/2-negative cancer patients with in-person genetic counseling allows informed decision-making while decreasing short-term anxiety, according to data presented at the 2015 San Antonio Breast Cancer Symposium.
An open-label, randomized, phase 2 study evaluated the all-oral triplet combination of ixazomib (an orally administered proteasome inhibitor) plus cyclophosphamide (at 2 different doses) and low-dose dexamethasone (ICd) as a 12-month induction therapy in previously untreated, transplant-ineligible patients with multiple myeloma (MM).
Presence of cytogenetic abnormalities (CAs) is considered to be an important prognostic factor in patients with multiple myeloma (MM), with some evidence suggesting that bortezomib-based combinations may overcome the poor prognosis associated with CAs, such as t(4;14), t(14;16), or deletion of 17p (del [17p]).
Imatinib mesylate (IM) at 400 mg/day is the standard of care as first-line therapy in patients with newly diagnosed, chronic-phase chronic myeloid leukemia (CP-CML).
In contrast to current recommendations to continue tyrosine kinase inhibitor therapy indefinitely, emerging evidence indicates that patients with sustained molecular responses (MRs) on imatinib therapy may achieve deep MRs and durable treatment-free remission with nilotinib in patients with chronic-phase chronic myeloid leukemia (CP-CML).
A collaborative program between Memorial Sloan Kettering Cancer Center in New York, NY, and the City of Hope in Duarte, CA, has helped educate nurses about survivorship care and facilitate their development at their own institutions.
A study evaluating a new model for education of primary care nurse practitioners (NPs) in oncology practice has shown effective delivery of essential basic care competencies.
To decrease barriers to transition for childhood cancer survivors, Children’s Mercy Hospital and the University of Kansas Cancer Center (KUCC), Mercy Hospital, Kansas City, MO, have collaborated to develop the Survivorship Transition Clinic (STC).
Although immunotherapy drugs targeting programmed cell death-1 (PD-1) have proved to be effective in patients with melanoma and lung cancer, new data from 2 recent studies suggest that these drugs may also be effective in patients with certain gastrointestinal cancers.
The first National Colorectal Cancer Awareness Month was designated in March 2000. Since then, organizations throughout the country have dedicated March to increasing awareness of this disease and encouraging Americans to be screened. Here are some statistics and current information about colorectal cancer (CRC).
Page 2 of 2
Results 11 - 20 of 20